Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Splicing factor YJU2 (YJU2), also known as coiled-coil domain-containing protein 94 (CCDC94), is an integral component of the spliceosome, the complex responsible for catalyzing the removal of introns from pre-mRNA and ligation of exons to form mature mRNA[1][2][7]. YJU2 plays a critical role in stabilizing the catalytic core structure of the spliceosome and facilitating the docking of the branch helix into the active site, thus ensuring efficient and precise mRNA splicing[7][2]. It has also been implicated in cellular protection from TP53-dependent apoptosis following DNA damage and participates in signaling pathways mediated by p53 class mediators[7][1][2]. Disruption of its function may contribute to disease processes, including cancer and some neurodegenerative diseases, though specific disease mechanisms and drug interactions have not yet been established[1][2][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Splicing factor YJU2 (YJU2).